Zynex (NASDAQ:ZYXI – Get Free Report) updated its third quarter earnings guidance on Thursday. The company provided EPS guidance of $0.05 for the period, compared to the consensus EPS estimate of $0.16. The company issued revenue guidance of $50.0, compared to the consensus revenue estimate of $60.13 million. Zynex also updated its FY 2024 guidance to 0.200- EPS.
Analyst Upgrades and Downgrades
ZYXI has been the subject of several research analyst reports. Royal Bank of Canada lowered their price objective on Zynex from $15.00 to $12.00 and set an outperform rating for the company in a report on Friday. HC Wainwright lowered their price target on Zynex from $21.00 to $16.00 and set a buy rating for the company in a report on Friday.
Get Our Latest Analysis on ZYXI
Zynex Stock Performance
Zynex (NASDAQ:ZYXI – Get Free Report) last issued its earnings results on Thursday, July 25th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). The business had revenue of $49.88 million during the quarter, compared to the consensus estimate of $51.99 million. Zynex had a return on equity of 16.34% and a net margin of 4.33%. The business’s revenue was up 11.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.09 EPS. As a group, analysts expect that Zynex will post 0.51 EPS for the current fiscal year.
Zynex Company Profile
Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.
Recommended Stories
- Five stocks we like better than Zynex
- What Are Dividend Champions? How to Invest in the Champions
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- What is the Dogs of the Dow Strategy? Overview and Examples
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.